MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1509038

Медицинская библиотека · The New England journal of medicine · 2015

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Ellis Stephen G, Kereiakes Dean J, Metzger D Christopher, Caputo Ronald P, Rizik David G, Teirstein Paul S, Litt Marc R, Kini Annapoorna, Kabour Ameer, Marx Steven O, Popma Jeffrey J, McGreevy Robert, Zhang Zhen, Simonton Charles, Stone Gregg W, ABSORB III Investigators

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascular scaffolds have been developed to attempt to improve long-term outcomes.

METHODS

In this large, multicenter, randomized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to receive an everolimus-eluting bioresorbable vascular (Absorb) scaffold (1322 patients) or an everolimus-eluting cobalt-chromium (Xience) stent (686 patients). The primary end point, which was tested for both noninferiority (margin, 4.5 percentage points for the risk difference) and superiority, was target-lesion failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization) at 1 year.

RESULTS

Target-lesion failure at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (difference, 1.7 percentage points; 95% confidence interval, -0.5 to 3.9; P=0.007 for noninferiority and P=0.16 for superiority). There was no significant difference between the Absorb group and the Xience group in rates of cardiac death (0.6% and 0.1%, respectively; P=0.29), target-vessel myocardial infarction (6.0% and 4.6%, respectively; P=0.18), or ischemia-driven target-lesion revascularization (3.0% and 2.5%, respectively; P=0.50). Device thrombosis within 1 year occurred in 1.5% of patients in the Absorb group and in 0.7% of patients in the Xience group (P=0.13).

CONCLUSIONS

In this large-scale, randomized trial, treatment of noncomplex obstructive coronary artery disease with an everolimus-eluting bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt-chromium stent, was within the prespecified margin for noninferiority with respect to target-lesion failure at 1 year. (Funded by Abbott Vascular; ABSORB III ClinicalTrials.gov number, NCT01751906.).

Для цитирования: Ellis Stephen G, Kereiakes Dean J, Metzger D Christopher, Caputo Ronald P, Rizik David G, Teirstein Paul S, Litt Marc R, Kini Annapoorna, Kabour Ameer, Marx Steven O, Popma Jeffrey J, McGreevy Robert, Zhang Zhen, Simonton Charles, Stone Gregg W, ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.. The New England journal of medicine. 2015. DOI: 10.1056/nejmoa1509038.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.